Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates
- Dr. Garry Neil and Chris Sullivan promoted to Chief Executive Officer and Chief Financial Officer, respectively
- Announced plans to initiate a Phase 2 randomized, double-blind, placebo-controlled trial in moderate to severe Non-eosinophilic Asthma (NEA) patients. Topline data anticipated in the fourth quarter of 2022
- Pipeline optimized to focus on most promising candidates and indications
- Cash and cash equivalents of $54.6 million as of December 31, 2021
WAYNE, Pa. and ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet need in immunology and rare genetic diseases, today announced business updates and year-end financial results for 2021.
“2021 was an important year for Avalo in that the Company produced compelling data for AVTX-002 in both acute and chronic inflammatory diseases. Furthermore, it positioned the Company to launch a placebo-controlled trial in NEA (AVTX-002), as well as two rare disease pivotal trials in 2022,” said Dr. Garry Neil, Chief Executive Officer of Avalo Therapeutics. “We are focused on the operational execution of these programs and their corresponding milestones, which have great potential to drive shareholder value in the coming year. We believe the recent pipeline prioritization will allow for greater focus on these most promising programs while also allowing for a reduction in cash burn.”
Business Updates:
- Promoted Dr. Garry Neil to Chief Executive Officer and Chris Sullivan to Chief Financial Officer. Dr. Neil brings to this position extensive clinical development and leadership experience in the biopharmaceutical industry including his current role as Chairman of the Board for Arena Pharmaceuticals and prior senior positions in leading pharmaceutical companies including Johnson & Johnson, Merck and AstraZeneca. Mr. Sullivan brings strong financial leadership to Avalo from his prior senior level finance/accounting positions for various Nasdaq-listed life science companies and Ernst & Young.
- Appointed June Almenoff M.D., Ph.D., and Mitchell Chan to the Board of Directors. Dr. Almenoff brings close to 25 years of leadership experience focused on research and development and commercialization including her time as the President and Chief Medical Officer of Furiex Pharmaceuticals. Mr. Chan has more than 15 years of finance experience in the life sciences industry including his time as Chief Financial Officer of Viela Bio and senior financial positions at AstraZeneca and Genentech-Roche.
- Announced plans to conduct a new Phase 2 randomized, double-blind, placebo-controlled trial of AVTX-002 for the treatment of moderate to severe NEA; top-line data anticipated in the fourth quarter of 2022. NEA is subtype of asthma with a poor prognosis that encompasses approximately half of asthma patients. Biomarker data suggests that LIGHT plays a strong role in inflammation and airway remodeling in NEA and support the development of AVTX-002 for poorly controlled NEA patients.
- Optimized the pipeline, with Avalo winding down internal development efforts of AVTX-006 in lymphatic malformations and AVTX-007 for the treatment of multiple myeloma (as previously announced) while pausing current development efforts for AVTX-802 (MPI-CDG). We plan to pursue strategic alternatives for AVTX-006. Avalo also intends to focus on placebo-controlled trials for AVTX-002 going forward, starting with NEA. We will therefore not be moving forward with the uncontrolled cohort of AVTX-002 in ulcerative colitis (UC) patients. Avalo will consider planning for a possible randomized, double-blind, placebo-controlled clinical study in moderate to severe refractory patients with inflammatory bowel disease.
- Presented data from Phase 1b, open-label, dose-escalation, signal-finding, multi-center study evaluated the safety, tolerability, pharmacokinetics, and short-term efficacy of AVTX-002 in adults with moderate to severe, active Crohn’s disease (CD) who have previously failed anti-tumor necrosis factor alpha (anti-TNFα) treatment. Fifty percent (4/8 patients) demonstrated evidence of mucosal healing as determined by colonoscopy and adjudicated by a central reader with one patient achieving remission (SES-CD=0).
Program Updates and Milestones:
- AVTX-002: Anti-LIGHT monoclonal antibody (mAb) targeting immune-inflammatory diseases including Non-eosinophilic Asthma and inflammatory bowel disease (Crohn’s disease and Ulcerative Colitis).
- Non-eosinophilic Asthma: An investigational new drug (IND) application is active for AVTX-002 for the treatment of NEA and Avalo expects to initiate a Phase 2 randomized, double-blind, placebo-controlled Phase 2 clinical trial in 80 patients with poorly controlled NEA. Top-line data from the trial are currently expected in the fourth quarter of 2022.
- Inflammatory Bowel Disease: Presented positive Phase 1b data in CD with efficacy signal demonstrated in heavily pre-treated patients supports further evaluation in inflammatory bowel disease patients’ refractory to three or more treatments, including anti-TNFα and other biologics. As Avalo intends to focus on placebo-controlled trials for AVTX-002 going forward, we will not be moving forward with the uncontrolled cohort of AVTX-002 in UC patients. Avalo will consider planning for a possible randomized, double-blind, placebo-controlled clinical study in moderate to severe refractory patients in inflammatory bowel disease.
- AVTX-007: Anti-IL-18 mAb targeting adult-onset Still’s disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA).
- AOSD: AVTX-007 is being evaluated in a multicenter, Phase 1b study in 12 refractory or steroid-dependent patients with AOSD in two cohorts. Management is currently reviewing preliminary data and the path forward related to this indication. Top-line data currently expected in 2023, though this is subject to change and refinement pending finalization of the review.
- Multiple Myeloma: Data from a multicenter, Phase 1b study in relapsed and refractory multiple myeloma patients indicated AVTX-007 was generally safe and well tolerated at doses up to 14mg/kg. Additionally, pharmacodynamic data indicate deep reductions in IL-18 levels occur withing 24-hours after dosing. However, as previously announced, due to a lack of efficacy signal Avalo is winding down internal development efforts in this indication.
- AVTX-006: Dual mTORc1/c2 small molecule inhibitor for lymphatic malformations.
- As a result of a portfolio prioritization review, Avalo is winding down internal development of AVTX-006 and has decided to pursue strategic alternatives for this program.
- AVTX-800 programs (AVTX-801, AVTX-802, and AVTX-803): Therapeutic doses of monosaccharide therapies for congenital disorders of glycosylation (CDGs).
- Avalo is in the process of initiating a single-center (US), double-blind (followed by an open-label extension) pivotal study of AVTX-803 in patients with leukocyte adhesion deficiency type II (LAD II) caused by loss-of-function mutation in the SLC35C1 gene, with pivotal trial data expected in the fourth quarter of 2022.
- Avalo and the study sponsor remain in dialogue with the FDA to align on a suitable clinical study design for AVTX-801 (PGM1-CDG). Pivotal trial data are expected in 2023. Avalo is currently working with the study sponsor to refine milestone timing.
- The Company is pausing internal development of AVTX-802 (MPI-CDG) at this time due to challenges with study feasibility.
2021 Financial Update:
As of December 31, 2021, Avalo had $54.6 million in cash and cash equivalents, representing a $35.7 million increase as compared to December 31, 2020. The increase was primarily driven by gross proceeds of approximately $72.2 million from underwritten public offerings and $35.0 million from a debt facility. Such increases were partially offset by operating expenditures, the majority of which were related to pipeline development.
Total operating expenses increased $8.0 million for the year ended December 31, 2021 as compared to the year ended December 31, 2020. The increase in operating expenses was largely driven by a $27.6 million increase in research and development expenses to support our maturing pipeline and a $4.4 million increase in general and administrative expenses, partially offset by a $25.5 million reduction in acquired in-process research and development expense as this charge in 2020 did not repeat.
Consolidated Balance Sheets
(In thousands, except share and per share data)
| December 31, | ||||||||
| 2021 | 2020 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 54,585 | $ | 18,919 | ||||
| Accounts receivable, net | 1,060 | 2,177 | ||||||
| Other receivables | 3,739 | 2,208 | ||||||
| Inventory, net | 38 | 3 | ||||||
| Prepaid expenses and other current assets | 2,372 | 2,660 | ||||||
| Restricted cash, current portion | 51 | 38 | ||||||
| Total current assets | 61,845 | 26,005 | ||||||
| Property and equipment, net | 2,695 | 1,607 | ||||||
| Other long-term asset | 1,000 | — | ||||||
| Intangible assets, net | 38 | 1,585 | ||||||
| Goodwill | 14,409 | 14,409 | ||||||
| Restricted cash, net of current portion | 227 | 149 | ||||||
| Total assets | $ | 80,214 | $ | 43,755 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,369 | $ | 2,574 | ||||
| Accrued expenses and other current liabilities | 16,519 | 11,310 | ||||||
| Income taxes payable | — | — | ||||||
| Current liabilities of discontinued operations | — | 1,341 | ||||||
| Total current liabilities | 19,888 | 15,225 | ||||||
| Notes payable, net | 32,833 | — | ||||||
| Royalty obligation | 2,000 | 2,000 | ||||||
| Deferred tax liability, net | 113 | 90 | ||||||
| Other long-term liabilities | 2,298 | 1,878 | ||||||
| Total liabilities | 57,132 | 19,193 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock—$0.001 par value; 200,000,000 shares authorized at December 31, 2021 and 2020; 112,794,203 and 75,004,127 shares issued and outstanding at December 31, 2021 and 2020, respectively | 113 | 75 | ||||||
| Preferred stock—$0.001 par value; 5,000,000 shares authorized at December 31, 2021 and 2020; 0 and 1,257,143 shares issued and outstanding at December 31, 2021 and 2020, respectively | — | 1 | ||||||
| Additional paid-in capital | 285,135 | 202,276 | ||||||
| Accumulated deficit | (262,166 | ) | (177,790 | ) | ||||
| Total stockholders’ equity | 23,082 | 24,562 | ||||||
| Total liabilities and stockholders’ equity | $ | 80,214 | $ | 43,755 | ||||
The consolidated balance sheets as of December 31, 2021 and 2020 have been derived from the audited financial statements, but do not include all of the information and footnotes required by accounting principles accepted in the United States for complete financial statements.
Consolidated Statements of Operations
(In thousands, except per share data)
| Year Ended December 31, | ||||||||
| 2021 | 2020 | |||||||
| Revenues: | ||||||||
| Product revenue, net | $ | 4,773 | $ | 6,699 | ||||
| License revenue | 625 | — | ||||||
| Total revenues, net | 5,398 | 6,699 | ||||||
| Operating expenses: | ||||||||
| Cost of product sales | 1,491 | 300 | ||||||
| Research and development | 59,835 | 32,193 | ||||||
| Acquired in-process research and development | — | 25,549 | ||||||
| General and administrative | 21,832 | 17,418 | ||||||
| Sales and marketing | 2,826 | 2,341 | ||||||
| Amortization expense | 1,548 | 1,741 | ||||||
| Total operating expenses | 87,532 | 79,542 | ||||||
| (82,134 | ) | (72,843 | ) | |||||
| Other (expense) income: | ||||||||
| Change in fair value of Investment in Aytu | — | 5,208 | ||||||
| Other (expense) income, net | (20 | ) | 409 | |||||
| Interest (expense) income, net | (2,391 | ) | 49 | |||||
| Total other (expense) income, net from continuing operations | (2,411 | ) | 5,666 | |||||
| Loss from continuing operations before income taxes | (84,545 | ) | (67,177 | ) | ||||
| Income tax benefit | (196 | ) | (2,793 | ) | ||||
| Loss from continuing operations | $ | (84,349 | ) | $ | (64,384 | ) | ||
| (Loss) income from discontinued operations | (27 | ) | 884 | |||||
| Net loss | $ | (84,376 | ) | $ | (63,500 | ) | ||
| Net (loss) income per share of common stock, basic and diluted: | ||||||||
| Continuing operations | $ | (0.83 | ) | $ | (0.87 | ) | ||
| Discontinued operations | 0.00 | 0.01 | ||||||
| Net loss per share of common stock, basic and diluted | $ | (0.83 | ) | $ | (0.86 | ) | ||
| Net (loss) income per share of preferred stock, basic and diluted: | ||||||||
| Continuing operations | $ | (4.15 | ) | $ | (4.38 | ) | ||
| Discontinued operations | 0.00 | 0.06 | ||||||
| Net loss per share of preferred stock, basic and diluted | $ | (4.15 | ) | $ | (4.32 | ) | ||
The consolidated statements of operations for the years ended December 31, 2021 and 2020 have been derived from the audited financial statements, but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.
About Avalo Therapeutics
Avalo Therapeutics is a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology and rare genetic diseases. The Company has built a diverse portfolio of innovative therapies to deliver meaningful medical impact for patients in urgent need. The Company’s clinical candidates commonly have a proven mechanistic rationale, biomarkers and/or an established proof-of-concept to expedite and increase the probability of success.
For more information about Avalo, please visit www.avalotx.com.
Forward-Looking Statements
This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: the future financial and operational outlook; the development of product candidates or products; timing and success of trial results and regulatory review; potential attributes and benefits of product candidates; and other statements that are not historical. These statements are based upon the current beliefs and expectations of Avalo’s management but are subject to significant risks and uncertainties, including: drug development costs, timing and other risks, including reliance on investigators and enrollment of patients in clinical trials, which might be slowed by the COVID-19 pandemic; reliance on key personnel, including as a result of recent management changes; regulatory risks; Avalo’s cash position and the potential need for it to raise additional capital; general economic and market risks and uncertainties, including those caused by the COVID-19 pandemic and tensions in Ukraine; and those other risks detailed in Avalo’s filings with the SEC. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For media and investor inquiries
Chris Brinzey
Westwicke, an ICR Company
Chris.brinzey@westwicke.com
339-970-2843
or
Maxim Jacobs, CFA
Vice President, Investor Relations
Avalo Therapeutics
mjacobs@avalotx.com
610-254-4201
